

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
31 March 2005 (31.03.2005)

PCT

(10) International Publication Number
WO 2005/027921 A1

(51) International Patent Classification⁷: **A61K 31/59**,
A61P 19/10, 3/02, 19/00, 35/00, 3/04, 21/00, A61K
31/663, 31/675

(21) International Application Number:
PCT/IB2004/002935

(22) International Filing Date:
6 September 2004 (06.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/504,008 19 September 2003 (19.09.2003) US

(71) Applicant (for all designated States except US): **PFIZER
PRODUCTS INC.** [US/US]; Eastern Point Road, Groton,
CT 06340 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **LEE, Andrew, George**
[US/US]; Pfizer Global Research and Development, 50 Pe-
quot Avenue, New London, CT 06320 (US).

(74) Agent: **FULLER, Grover, F., Jr.**; c/o Lawrence, Jackie,
Pfizer Inc. MS8260-1615, Eastern Point Road, Groton, CT
06320 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING COMBINATIONS OF 2-ALKYLIDENE-19-NOR-VITAMIN D DERIVATIVES AND A BISPHOSPHONATE**

(57) Abstract: The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2 alkylidene-19-nor-vitamin D derivative and a bisphosphonate. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)1 α ,25-dihydroxyvitamin D₃ and a bisphosphonate.



WO 2005/027921 A1

**PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING
COMBINATIONS OF 2-ALKYLIDENE-19-NOR-VITAMIN D DERIVATIVES AND A
BISPHOSPHONATE**

5 Field of the Invention

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and a bisphosphonate. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a therapeutically effective amount of 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ and a bisphosphonate.

Background of the Invention

15 Vitamin D is a general term that refers to a group of steroid molecules. The active form of vitamin D, which is called 1,25-dihydroxyvitamin D₃ (1,25-dihydroxycholecalciferol), is biosynthesized in humans by the conversion of 7-dehydrocholesterol to vitamin D₃ (cholecalciferol). This conversion takes place in the skin and requires UV radiation, which is typically from sunlight. Vitamin D₃ is then
20 metabolized in the liver to 25-hydroxyvitamin D₃ (25-hydroxycholecalciferol), which is then further metabolized in the kidneys to the active form of vitamin D, 1,25-dihydroxyvitamin D₃. 1,25-dihydroxyvitamin D₃ is then distributed throughout the body where it binds to intracellular vitamin D receptors.

The active form of vitamin D is a hormone that is known to be involved in mineral metabolism and bone growth and facilitates intestinal absorption of calcium.

Vitamin D analogs are disclosed in U.S. Patent No. 5,843,928, issued December 1, 1998. The compounds disclosed are 2-alkylidene-19-nor-vitamin D derivatives and are characterized by low intestinal calcium transport activity and high bone calcium mobilization activity when compared to 1,25-dihydroxyvitamin D₃.

30 The present invention provides for methods of treatment using a combination of a 2-alkylidene-19-nor-vitamin D derivative, and particularly the compound 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃, (also known as 2MD), and a bisphosphonate. The present invention also provides a pharmaceutical composition comprising a 2-alkylidene-19-nor-vitamin D derivative, and particularly the compound

2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃, (also known as 2MD), and a bisphosphonate.

Summary of the Invention

5 The present invention provides pharmaceutical compositions comprising the compound 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃, and a bisphosphonate. Particular embodiments of this invention are pharmaceutical compositions comprising the compound 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃, and a bisphosphonate wherein the bisphosphonate is selected
10 from tiludronate, alendronate, zoledronate, ibandronate, risedronate, etidronate, clodronate or pamidronate. More particularly, the present invention provides pharmaceutical compositions comprising the compound 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃, and alendronate or risedronate. The present invention also provides a method of treating senile osteoporosis, postmenopausal
15 osteoporosis, bone fracture, bone graft, breast cancer, prostate cancer, obesity, osteopenia, male osteoporosis, frailty, muscle damage or sarcopenia, the method comprising administering to a patient in need thereof a therapeutically effective amount of 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ and a therapeutically effective amount of a bisphosphonate. A particular embodiment of the method of
20 treatment is the method as described immediately above wherein the 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ and bisphosphonate are administered orally. Additional embodiments of this invention are methods of treatment as described above wherein the 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered parenterally or transdermally. Further embodiments of this invention
25 are methods of treatment wherein the bisphosphonate is selected from tiludronate, alendronate, zoledronate, ibandronate, risedronate, etidronate, clodronate or pamidronate. Particular embodiments of this invention are the methods of treatment wherein the bisphosphonate is alendronate or risedronate.

Detailed Description of the Invention

30 The present invention relates to pharmaceutical compositions and methods of treating metabolic bone disease, senile osteoporosis, postmenopausal osteoporosis, steroid induced osteoporosis, low bone turnover osteoporosis, osteomalacia, renal

osteodystrophy, psoriasis, multiple sclerosis, diabetes mellitus, host versus graft rejection, transplant rejection, rheumatoid arthritis, asthma, bone fractures, bone grafts, acne, alopecia, dry skin, insufficient skin firmness, insufficient sebum secretion, wrinkles, hypertension, leukemia, colon cancer, breast cancer, prostate cancer, obesity, osteopenia, male osteoporosis, hypogonadism, andropause, frailty, muscle damage, sarcopenia, osteosarcoma, hypocalcemic tetany, hypoparathyroidism, rickets, vitamin D deficiency, anorexia, low bone mass resulting from aggressive athletic behavior, and for enhancement of peak bone mass in adolescence and treatment and prevention of a second hip fracture using a combination of a 2-alkylidene-19-nor-vitamin D derivative and a bisphosphonate.

In a preferred embodiment, the present invention relates to a method of treating metabolic bone disease, senile osteoporosis, postmenopausal osteoporosis, steroid induced osteoporosis, low bone turnover osteoporosis, osteomalacia, renal osteodystrophy, psoriasis, multiple sclerosis, diabetes mellitus, host versus graft rejection, transplant rejection, rheumatoid arthritis, asthma, bone fractures, bone grafts, acne, alopecia, dry skin, insufficient skin firmness, insufficient sebum secretion, wrinkles, hypertension, leukemia, colon cancer, breast cancer, prostate cancer, obesity, osteopenia, male osteoporosis, hypogonadism, andropause, frailty, muscle damage, sarcopenia, osteosarcoma, hypocalcemic tetany, hypoparathyroidism, rickets, vitamin D deficiency, anorexia, low bone mass resulting from aggressive athletic behavior, and for enhancement of peak bone mass in adolescence and prevention of second hip fracture using 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ and a bisphosphonate.

In a preferred embodiment, the methods of treatment using the combination are senile osteoporosis, postmenopausal osteoporosis, bone fractures, bone grafts, breast cancer, prostate cancer, obesity, osteopenia, male osteoporosis, frailty, muscle damage and sarcopenia.

Osteopenia is a thinning of the bones, but less than is seen with osteoporosis and is the stage before true osteoporosis. The World Health Organization has developed diagnostic categories based on bone mass density (BMD) to indicate if a person has normal bones, has osteopenia or has osteoporosis. Normal bone density is within one standard deviation (+1 or -1) of the young adult mean bone density. Osteopenia (low bone mass) is defined as a bone density 1 to 2.5 standard deviations below the young adult mean (-1 to -2.5), and osteoporosis is defined as a

bone density which is 2.5 standard deviations or more below the young adult mean (>-2.5).

Hypogonadism is generally defined as inadequate gonadal function, as manifested by deficiencies in gametogenesis and/or the secretion of gonadal hormones, which can result in retardation of puberty and/or reproductive insufficiency. There are three main types of hypogonadism: 1) primary hypogonadism; 2) secondary hypogonadism and 3) resistance hypogonadism. In primary hypogonadism damage to the Leydig cells impairs androgen production. In secondary hypogonadism disorder of the hypothalamus or pituitary impairs gonadotropin secretion and in resistance hypogonadism, the body response to androgen is inadequate.

Rickets is a childhood disorder involving softening and weakening of the bones, primarily caused by lack of vitamin D, calcium, and/or phosphate.

Anorexia is a disease that has the following characteristics: refusal to maintain body weight at or above a minimally normal weight for age and height (e.g., weight loss leading to maintenance of body weight less than 85% of that expected; or failure to make expected weight gain during period of growth, leading to body weight less than 85% of that expected); intense fear of gaining weight or becoming fat, even though underweight; and disturbance in the way in which one's body weight or shape is experienced, undue influence of body weight or shape on self-evaluation, or denial of the seriousness of the current low body weight. The compounds and combinations of the present invention can be used to treat anorexia and can be used to treat bone loss associated with anorexia.

Another condition that can be treated using the compounds and combinations of the present invention is bone loss associated with aggressive athletic behavior, particularly in women. Aggressive participation in exercise, athletics or sports can result in bone loss, which is usually accompanied in women by amenorrhea. Men who also exhibit aggressive athletic behavior also exhibit bone loss.

Andropause (also called male menopause or viropause) is a natural occurrence in men that typically happens between the age of forty and fifty-five. Andropause is a decline in the level of the hormone testosterone. As testosterone levels decline, and men enter andropause, various changes or conditions may be observed including decreased energy and strength, increased body fat, osteoporosis, depression, decreased mental acuity, inability to maintain muscle, cardiovascular

disease, atherosclerosis, decreased libido, decreased strength of orgasms, erectile dysfunction, increased irritability, and aching and stiff joints, particularly in the hands and feet. In addition, males undergoing or having undergone andropause can have gynecomastia, serum lipid disorders, including hypercholesterolemia, reduced
5 vascular reactivity, hypogonadism, and benign prostatic hyperplasia.

Frailty is characterized by the progressive and relentless loss of skeletal muscle mass resulting in a high risk of injury from fall, difficulty in recovery from illness, prolongation of hospitalization, and long-term disability requiring assistance in daily living. The reduction of muscle mass, physical strength and physical
10 performance typically leads to diminished quality of life, loss of independence, and mortality. Frailty is normally associated with aging, but may also result when muscle loss and reduced strength occur due to other factors, such as disease-induced cachexia, immobilization, or drug-induced sarcopenia. Another term that has been used to denote frailty is sarcopenia, which is a generic term for the loss of skeletal
15 muscle mass, or quality. Examples of skeletal muscle properties that contribute to its overall quality include contractility, fiber size and type, fatiguability, hormone responsiveness, glucose uptake/metabolism, and capillary density. Loss of muscle quality, even in the absence of loss of muscle mass, can result in loss of physical strength and impaired physical performance.

20 The term 'muscle damage' as used herein is damage to any muscle tissue. Muscle damage can result from physical trauma to the muscle tissue as the result of accidents, athletic injuries, endocrine disorders, disease, wounds or surgical procedures. The methods of the present invention are useful for treating muscle damage by facilitating muscle damage repair.

25 Osteoporosis in the elderly woman is determined by the amount of peak bone mass gained in adolescence leading to adulthood, the premenopausal maintenance of such peak bone mass, and the rate of postmenopausal bone mass loss. Determinants of peak bone mass include genetic, nutritional, weight loading (exercise), and environmental factors. Enhancement of peak bone mass in
30 adolescence is therefore desirable in order to maximize the skeletal mass in order to prevent the development of osteoporosis later in life. Likewise, enhancement of peak bone mass in adolescence for males is also desirable.

Hip fracture has a significant impact on medical resources and patient morbidity and mortality. Few patients admitted with a hip fracture are considered for

prophylactic measures aimed at the reduction of further fracture risk. Currently, 10-13% of patients will later sustain a second hip fracture. Of patients who suffered a second hip fracture, fewer patients maintained their ability to walk independently after the second fracture than did so after the first (53 and 91% respectively, $P < 0.0005$).

- 5 Pearse E.O. et al., *Injury*, 2003, 34(7), 518-521. Following a second hip fracture, patients' level of mobility determined their future social independence. Older patients and those with a history of multiple falls had a shorter time interval between fractures. Second hip fracture has a significant further impact on patients' mobility and social independence. It is therefore desirable to have new methods for the prevention of a
- 10 second hip fracture.

Osteosarcoma is a relatively common, highly malignant primary bone tumor that has a tendency to metastasize to the lungs. Osteosarcoma is most common in persons 10 to 20, though it can occur at any age. About half of all osteosarcomas are located in the region of the knee but it can be found in any bone. Pain and a

15 mass are the usual symptoms of osteosarcoma. Typical treatment for osteosarcoma is chemotherapy in combination with surgery. Either preoperative or postoperative chemotherapy with agents such as methotrexate, doxorubicin, cisplatin or carboplatin can be used to treat the osteosarcoma.

Hypoparathyroidism is a tendency to hypocalcemia, often associated with

20 chronic tetany resulting from hormone deficiency, characterized by low serum calcium and high serum phosphorus levels. Hypoparathyroidism usually follows accidental removal of or damage to several parathyroid glands during thyroidectomy. Transient hypoparathyroidism is common following subtotal thyroidectomy and occurs permanently in less than three percent of expertly performed thyroidectomies.

25 Hypocalcemic tetany is a form of tetany resulting from hypocalcemia. Hypocalcemia is characterized by a decrease in total plasma calcium concentration below 8.8 mg/dL (milligrams/deciliter) in the presence of normal plasma protein concentration. Tetany may be overt with spontaneous symptoms or latent. Tetany, when overt, is characterized by sensory symptoms such as paresthesias of the lips,

30 tongue, fingers and feet; carpopedal spasm, which may be prolonged and painful; generalized muscle aching; and spasm of facial musculature. Latent tetany requires provocative tests to elicit and generally occurs at less severely decreased plasma calcium concentrations, such as 7 to 8 mg/dL. Hypocalcemic tetany is also observed in veterinary practice in animals. For example, hypocalcemic tetany in horses is a

rare condition associated with acute depletion of serum-ionized calcium and sometimes with alterations in serum concentrations of magnesium and phosphate. It occurs after prolonged physical exertion or transport (transport tetany) and in lactating mares (lactation tetany). Signs are variable and relate to neuromuscular hyperirritability.


The present invention is also concerned with pharmaceutical compositions for treating metabolic bone disease, senile osteoporosis, postmenopausal osteoporosis, steroid induced osteoporosis, low bone turnover osteoporosis, osteomalacia, renal osteodystrophy, psoriasis, multiple sclerosis, diabetes mellitus, host versus graft rejection, transplant rejection, rheumatoid arthritis, asthma, bone fractures, bone grafts, acne, alopecia, dry skin, insufficient skin firmness, insufficient sebum secretion, wrinkles, hypertension, leukemia, colon cancer, breast cancer, prostate cancer, obesity, osteopenia, male osteoporosis, hypogonadism, andropause, frailty, muscle damage, sarcopenia, osteosarcoma, hypocalcemic tetany, hypoparathyroidism, rickets, vitamin D deficiency, anorexia, low bone mass resulting from aggressive athletic behavior, and for enhancement of peak bone mass in adolescence and treatment and prevention of a second hip fracture comprising a 2-alkylidene-19-nor-vitamin D derivative, such as a compound of Formula I, and a bisphosphonate and a carrier, solvent, diluent and the like.

In one embodiment, the combinations of this invention comprise a therapeutically effective amount of a first compound, said first compound being an 2-alkylidene-19-nor-vitamin D derivative, such as a compound of Formula I; and a therapeutically effective amount of a second compound, the second compound being a bisphosphonate.

A particularly preferred combination is a combination of 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ and a bisphosphonate.

2-Alkylidene-19-nor-vitamin D derivatives that can be used in the present invention are disclosed U.S. Patent No. 5,843,928, which derivatives are characterized by the general formula I shown below:


30



where Y_1 and Y_2 , which may be the same or different, are each selected from
 5 the group consisting of hydrogen and a hydroxy-protecting group, R_6 and R_8 , which
 may be the same or different, are each selected from the group consisting of
 hydrogen, alkyl, hydroxyalkyl and fluoroalkyl, or, when taken together represent the
 group $-(CH_2)_x-$ where X is an integer from 2 to 5, and where the group R represents
 any of the typical side chains known for vitamin D type compounds.

10 More specifically R can represent a saturated or unsaturated hydrocarbon
 radical of 1 to 35 carbons, that may be straight-chain, branched or cyclic and that
 may contain one or more additional substituents, such as hydroxy- or protected-
 hydroxy groups, fluoro, carbonyl, ester, epoxy, amino or other heteroatomic groups.
 Preferred side chains of this type are represented by the structure below:


15



where the stereochemical center (corresponding to C-20 in steroid
 20 numbering) may have the R or S configuration (i.e., either the natural configuration
 about carbon 20 or the 20-epi configuration), and where Z is selected from Y , $-OY$,

—CH₂OY, —C≡CY and —CH=CHY, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, —COR⁵ and a radical of the structure:

5



where m and n, independently, represent the integers from 0 to 5, where R¹ is
 10 selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C₁₋₅-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R², R³ and R⁴, independently, is selected from deuterium, deuterioalkyl, hydrogen, fluoro, trifluoromethyl and C₁₋₅ alkyl, which may be straight-chain or branched, and
 15 optionally, bear a hydroxy or protected-hydroxy substituent, and where R¹ and R², taken together, represent an oxo group, or an alkylidene group, =CR²R³, or the group —(CH₂)_p—, where p is an integer from 2 to 5, and where R³ and R⁴, taken together, represent an oxo group, or the group —(CH₂)_q—, where q is an integer from 2 to 5, and where R⁵ represent hydrogen, hydroxy, protected hydroxy, or C₁₋₅ alkyl and
 20 wherein any of the CH-groups at positions 20, 22 or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups —CH(CH₃)—, —CH(R³)—, or —CH(R²)— at positions 20, 22 and 23, respectively, may be replaced by an oxygen or sulfur atom.


The wavy line to the methyl substituent at C-20 indicates that carbon 20 may
 25 have either the R or S configuration.

Specific important examples of side chains with natural 20R-configuration are the structures represented by formulas (a), (b), (c), (d) and (e) below, i.e., the side chain as it occurs in 25-hydroxyvitamin D₃ (a); vitamin D₃ (b); 25-hydroxyvitamin D₂ (c); vitamin D₂ (d); and the C-24 epimer of 25-hydroxyvitamin D₂ (e);


30

(a)

10




5




(b)

(c)




10



(d)

15



(e)

20

As used herein, the term "hydroxy-protecting group" signifies any group commonly used for the temporary protection of hydroxy functions, such as for example, alkoxycarbonyl, acyl, alkylsilyl or alkylarylsilyl groups (hereinafter referred to simply as "silyl" groups), and alkoxyalkyl groups. Alkoxycarbonyl protecting groups are alkyl-O-CO- groupings such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, tert-

25

butoxycarbonyl, benzyloxycarbonyl or allyloxycarbonyl. The term "acyl" signifies an alkanoyl group of 1 to 6 carbons, in all of its isomeric forms, or a carboxyalkanoyl group of 1 to 6 carbons, such as an oxalyl, malonyl, succinyl, or glutaryl group, or an aromatic acyl group such as benzoyl, or a halo, nitro or alkyl substituted benzoyl group. The term "alkyl", except as otherwise specified herein, denotes a straight-chain or branched alkyl radical of 1 to 10 carbons, in all its isomeric forms. Alkoxyalkyl protecting groups are groupings such as methoxymethyl, ethoxymethyl, methoxyethoxymethyl, or tetrahydrofuranyl and tetrahydropyranyl. Preferred silyl-protecting groups are trimethylsilyl, triethylsilyl, t-butyl dimethylsilyl, dibutylmethylsilyl, diphenylmethylsilyl, phenyldimethylsilyl, diphenyl-t-butylsilyl and analogous alkylated silyl radicals. The term "aryl", except as otherwise specified herein, specifies a phenyl-, or any alkyl-, nitro- or halo- substituted phenyl group.

A "protected hydroxy" group is a hydroxy group derivatized or protected by any of the above groups commonly used for the temporary or permanent protection of hydroxy functions, e.g., the silyl, alkoxyalkyl, acyl or alkoxycarbonyl groups, as previously defined. The terms "hydroxyalkyl", "deuteroalkyl" and "fluoroalkyl" refer to any alkyl radical substituted by one or more hydroxy, deuterium or fluoro groups respectively.

It should be noted in this description that the term "24-homo" refers to the addition of one methylene group and the term "24-dihomo" refers to the addition of two methylene groups at the carbon 24 position in the side chain. Likewise, the term "trihomo" refers to the addition of three methylene groups. Also, the term "26,27-dimethyl" refers to the addition of a methyl group at the carbon 26 and 27 positions so that for example R^3 and R^4 are ethyl groups. Likewise, the term "26,27-diethyl" refers to the addition of an ethyl group at the 26 and 27 positions so that R^3 and R^4 are propyl groups.

In the following lists of compounds, the particular alkylidene substituent attached at the carbon 2 position should be added to the nomenclature. For example, if a methylene group is the alkylidene substituent, the term "2-methylene" should precede each of the named compounds. If an ethylene group is the alkylidene substituent, the term "2-ethylene" should precede each of the named compounds, and so on. In addition, if the methyl group attached at the carbon 20 position is in its epi or unnatural configuration, the term "20(S)" or "20-epi" should be

included in each of the following named compounds. The named compounds could also be of the vitamin D₂ type if desired.

Specific and preferred examples of the 2-alkylidene-compounds of structure I when the side chain is unsaturated are:


- 5 19-nor-24-homo-1,25-dihydroxy-22-dehydrovitamin D₃;
 19-nor-24-dihomo-1,25-dihydroxy-22-dehydrovitamin D₃;
 19-nor-24-trihomo-1,25-dihydroxy-22-dehydrovitamin D₃;
 19-nor-26,27-dimethyl-24-homo-1,25-dihydroxy-22-dehydrovitamin D₃;
 19-nor-26,27-dimethyl-24-dihomo-1,25-dihydroxy-22-dehydrovitamin D₃;
10 19-nor-26,27-dimethyl-24-trihomo-1,25-dihydroxy-22-dehydrovitamin D₃;
 19-nor-26,27-diethyl-24-homo-1,25-dihydroxy-22-dehydrovitamin D₃;
 19-nor-26,27-diethyl-24-dihomo-1,25-dihydroxy-22-dehydrovitamin D₃;
 19-nor-26,27-diethyl-24-trihomo-1,25-dihydroxy-22-dehydrovitamin D₃;
 19-nor-26,27-dipropyl-24-homo-1,25-dihydroxy-22-dehydrovitamin D₃;
15 19-nor-26,27-dipropyl-24-dihomo-1,25-dihydroxy-22-dehydrovitamin D₃; and
 19-nor-26,27-dipropyl-24-trihomo-1,25-dihydroxy-22-dehydrovitamin D₃.

Specific and preferred examples of the 2-alkylidene-compounds of structure I when the side chain is saturated are:

- 19-nor-24-homo-1,25-dihydroxyvitamin D₃;
20 19-nor-24-dihomo-1,25-dihydroxyvitamin D₃;
 19-nor-24-trihomo-1,25-dihydroxyvitamin D₃;
 19-nor-26,26-dimethyl-24-homo-1,25-dihydroxyvitamin D₃;
 19-nor-26,27-dimethyl-24-dihomo-1,25-dihydroxyvitamin D₃;
 19-nor-26,27-dimethyl-24-trihomo-1,25-dihydroxyvitamin D₃;
25 19-nor-26,27-diethyl-24-homo-1,25-dihydroxyvitamin D₃;
 19-nor-26,27-diethyl-24-dihomo-1,25-dihydroxyvitamin D₃;
 19-nor-26,27-diethyl-24-trihomo-1,25-dihydroxyvitamin D₃;
 19-nor-26,27-dipropyl-24-homo-1,25-dihydroxyvitamin D₃;
 19-nor-26,27-dipropyl-24-dihomo-1,25-dihydroxyvitamin D₃; and
30 19-nor-26,27-dipropyl-24-trihomo-1,25-dihydroxyvitamin D₃.

Polyphosphonates, including bisphosphonates, are useful as the second compound in the compositions and methods of the present invention. Exemplary polyphosphonates include polyphosphonates of the type disclosed in U.S. Patent 3,683,080. Preferred polyphosphonates are geminal diphosphonates (referred to

herein as bisphosphonates). Preferred bisphosphonates are those of general formula A



wherein

5 R^4 is H, OH or Cl; and

R^5 is

- (a) alkyl with 1 to 6 carbon atoms, optionally substituted with amino, alkylamino, dialkylamino or heterocyclyl;
 - (b) halogen;
 - (c) arylthio, preferably chlorosubstituted;
 - (d) cycloalkylamino with 5 to 7 carbons; or
 - (e) saturated five or six membered nitrogen containing heterocyclyl with one or two heteroatoms;
- or a pharmaceutically acceptable salt or prodrug thereof.

15 The "alkyl" groups in the "alkylamino" and "dialkylamino" groups within the definition of R^5 in formula A may have 1 to 5 carbon atoms and can be independently selected in the dialkylamino group. The term "heterocyclyl" within R^5 in formula A means a saturated or unsaturated 5 to 7 membered heterocyclic group with one or two rings and 1 to 3 heteroatoms, independently chosen from N, O and S. The term

20 "aryl" within the term "arylthio" in the definition of R^5 means a substituted or unsubstituted phenyl, furyl, thienyl or pyridyl group, or a fused ring system of any of these groups, such as naphthyl. When substituted, the aryl group within R^5 is substituted by one or more alkyl, alkoxy, halogen, amino, thiol, nitro, hydroxy, acyl, aryl or cyano groups.

25 Compounds of formula A include:

4-amino-1-hydroxybutylidene-1,1-bisphosphonate (alendronate), (3-amino-1-hydroxypropylidene)-bisphosphonate (pamidronate), [2-(2-pyridinyl)ethylidene]-bisphosphonate (piridronate), (dichloromethylene)bisphosphonic acid (clodronic acid) and its disodium salt (clodronate), N,N-dimethyl-3-amino-1-hydroxypropylidene-1,1-

bisphosphonate (mildronate, olpadronate), 1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-bisphosphonate (ibandronate), 1-hydroxy-2-(3-pyridyl)ethylidene-1,1-bisphosphonate (risedronate), 1-hydroxyethylidene-1,1-bisphosphonate (etidronate), 1-hydroxy-3-(1-pyrrolidinyl)propylidene-1,1-bisphosphonate (EB-1053), 1-hydroxy-2-(1-imidazolyl)ethylidene-1,1-bisphosphonate (zoledronate), 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethylidene-1,1-bisphosphonate (minodronate), 1-(4-chlorophenylthio)methylidene-1,1-bisphosphonate (tiludronate), 1-(cycloheptylamino)methylidene-1,1-bisphosphonate (cimadronate, incadronate), 6-amino-1-hydroxyhexylidene-1,1-bisphosphonate (neridronate).

The term bisphosphonate means the compound in its bisphosphonic acid form and pharmaceutically acceptable salts thereof. For example, the term alendronate as used herein encompasses alendronic acid (the free acid form) along with pharmaceutically acceptable salts thereof, such as alendronate sodium. Likewise, the term risedronate means risedronic acid and pharmaceutically acceptable salts thereof, such as risedronate sodium. Also included within the definition of bisphosphonate as used herein are the hydrolyzable ester forms of these compounds.

Tiludronate disodium is an especially preferred bisphosphonate. Ibandronate is an especially preferred bisphosphonate. Alendronate is an especially preferred bisphosphonate. Zoledronate is an especially preferred bisphosphonate. Other preferred bisphosphonates are 6-amino-1-hydroxy-hexylidene-bisphosphonate and 1-hydroxy-3(methylpentylamino)-propylidene-bisphosphonate. The polyphosphonates, including the bisphosphonates, may be administered in the form of the acid, or of a soluble alkali metal salt or alkaline earth metal salt. Hydrolyzable esters of the polyphosphonates are likewise included. Specific examples include ethane-1-hydroxy 1,1-diphosphonic acid, methane diphosphonic acid, pentane-1-hydroxy-1,1-diphosphonic acid, methane dichloro diphosphonic acid, methane hydroxy diphosphonic acid, ethane-1-amino-1,1-diphosphonic acid, ethane-2-amino-1,1-diphosphonic acid, propane-3-amino-1-hydroxy-1,1-diphosphonic acid, propane-N,N-dimethyl-3-amino-1-hydroxy-1,1-diphosphonic acid, propane-3,3-dimethyl-3-amino-1-hydroxy-1,1-diphosphonic acid, phenyl amino methane diphosphonic acid, N,N-dimethylamino methane diphosphonic acid, N(2-hydroxyethyl) amino methane diphosphonic acid, butane-4-amino-1-hydroxy-1,1-diphosphonic acid,

pentane-5-amino-1-hydroxy-1,1-diphosphonic acid, hexane-6-amino-1-hydroxy-1,1-diphosphonic acid and pharmaceutically acceptable esters and salts thereof.

Particularly preferred bisphosphonates used in the compositions and methods of the present invention include tiludronic acid, alendronic acid, zoledronic acid, 5 ibandronic acid, risedronic acid, etidronic acid, clodronic acid, and pamidronic acid and their pharmaceutically acceptable salts or prodrugs or salts of the prodrugs.

The bisphosphonates employed in the compositions and methods of this invention are known in the art and described in the literature. Tiludronic acid, related compounds, and salts thereof have been described in U.S. Patent Nos. 4,134,969; 10 4,578,376; 4,621,077; 4,876,248; 4,980,171; 5,405,994; and 5,656,288. U.S. Patent 5,405,994 discloses disodium tiludronate hemihydrate and disodium tiludronate monohydrate. U.S. Patent No. 5,656,288 discloses disodium tiludronate tetrahydrate.

Alendronate, as its monosodium salt trihydrate form which is marketed as Fosamax®, is described in U.S. Patent Nos. 4,621,077; 4,922,007; 5,019,651; 15 5,510,517 and 5,648,491. For example, alendronate, in the bisphosphonic acid form can be prepared as described in U.S. Patent 4,621,077 which procedure is reproduced below. A mixture of 1 mole of 4-aminobutyric acid, 1.5 moles of phosphorous acid and 500 cc anhydrous chlorobenzene, is heated up to 100° C. At this temperature, phosphorous trichloride in the amount of 1.5 mole is added under 20 strong stirring. The mixture is stirred at 100° C. for 3 1/2 hours until the dense phase is completely formed and is then allowed to cool. The solid is filtered, washed with a small amount of chlorobenzene and dissolved in water. The solution is heated to the boiling point for one hour, it is then cooled and decolorized with active carbon. The material is filtered and the product is precipitated with excess of hot methanol. The 25 crude material so obtained is heated under reflux for eight hours in 20% hydrochloric acid. The hydrochloric acid is removed by distillation and the residue is recrystallized from water. The product is 4-amino-1-hydroxybutan-1,1-biphosphonic acid in the form of a white crystalline powder.

Zoledronate, as its free acid monohydrate which is marketed as Zometa®, has 30 been described in U.S. Patent No. 4,939,130. Ibandronate is described in U.S. Patent No. 4,927,814. Piridronate is described in U.S. Patent No. 4,761,406. Clodronate is described in Belgium Patent 672,205 (1966) and *J. Org. Chem.* 1967, 32, 4111. Incadronate is disclosed in U.S. Patent No. 4,970,335. Risedronate, as its monosodium salt hemi-pentahydrate (2.5 H₂O) form and which is marketed as

Actonel[®], is described in U.S. Patent Nos. 5,583,122; 5,994,329; 6,015,801; 6,096,342 and 6,165,513. For example, risedronate can be prepared according to the following procedure which is set forth as Example 3 in U.S. Patent 5,583,122.

Synthesis of 2-(2-pyridyl)-1-hydroxy-ethane-1,1-diphosphonic acid. A 3-neck round-bottom flask fitted with a reflux condenser and a magnetic stir bar is charged with 6.94 grams (0.04 mole) 2-pyridine acetic acid 9.84 grams (0.14 mole) phosphorus acid, and 150 ml of chlorobenzene. This reaction mixture is heated on a boiling water bath, and 16.5 grams (0.12 mole) phosphorus trichloride is added dropwise with stirring. This reaction mixture is heated for 21/2 hours during which time a viscous yellow oil forms. The reaction mixture is then cooled in an ice bath and the chlorobenzene solution is decanted off from the solidified product. The reaction flask containing this solidified product is charged with 150 ml of water and heated in a boiling water bath for several hours. The hot solution is then filtered through Celite 545[®] (diatomaceous earth, Mallinckrodt Baker, Inc., Phillipsburg, NJ). 300 ml of methanol is added to the warm filtrate solution, and a precipitate develops. After cooling in ice for 1 hour, the precipitate is filtered off and then washed with methanol/water (1/1 volume/volume), methanol, and ether, and air dried. The product may be recrystallized from hot water. Yield is approximately 5.9 grams (52 %). The sample is characterized by P-31 and C-13 NMR.

The present invention is also concerned with pharmaceutical compositions for the treatment of metabolic bone disease, senile osteoporosis, postmenopausal osteoporosis, steroid induced osteoporosis, low bone turnover osteoporosis, osteomalacia, renal osteodystrophy, psoriasis, multiple sclerosis, diabetes mellitus, host versus graft rejection, transplant rejection, rheumatoid arthritis, asthma, bone fractures, bone grafts, acne, alopecia, dry skin, insufficient skin firmness, insufficient sebum secretion, wrinkles, hypertension, leukemia, colon cancer, breast cancer, prostate cancer, obesity, osteopenia, male osteoporosis, hypogonadism, andropause, frailty, muscle damage, sarcopenia, osteosarcoma, hypocalcemic tetany, hypoparathyroidism, rickets, vitamin D deficiency, anorexia, low bone mass resulting from aggressive athletic behavior, and for enhancement of peak bone mass in adolescence and prevention of second hip fracture comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative, such as a compound of Formula I, and a bisphosphonate and a carrier, solvent, diluent and the like.

It is noted that when compounds are discussed herein, it is contemplated that the compounds may be administered to a patient as a pharmaceutically acceptable salt, prodrug, or a salt of a prodrug. All such variations are intended to be included in the invention.

5 The term "patient in need thereof" means humans and other animals who have or are at risk of having metabolic bone disease, senile osteoporosis, postmenopausal osteoporosis, steroid induced osteoporosis, low bone turnover osteoporosis, osteomalacia, renal osteodystrophy, psoriasis, multiple sclerosis, diabetes mellitus, host versus graft rejection, transplant rejection, rheumatoid arthritis,
10 asthma, bone fractures, bone grafts, acne, alopecia, dry skin, insufficient skin firmness, insufficient sebum secretion, wrinkles, hypertension, leukemia, colon cancer, breast cancer, prostate cancer, obesity, osteopenia, male osteoporosis, hypogonadism, andropause, frailty, muscle damage, sarcopenia, osteosarcoma, hypocalcemic tetany, hypoparathyroidism, rickets, vitamin D deficiency, anorexia and
15 low bone mass resulting from aggressive athletic behavior and for enhancement of peak bone mass in adolescence and prevention of second hip fracture.

The term "treating", "treat" or "treatment" as used herein includes preventative (e.g., prophylactic), palliative and curative treatment.

By "pharmaceutically acceptable" it is meant the carrier, diluent, excipients,
20 and/or salts or prodrugs must be compatible with the other ingredients of the formulation, and not deleterious to the patient.

The term "prodrug" means a compound that is transformed *in vivo* to yield a compound of the present invention. The transformation may occur by various mechanisms, such as through hydrolysis in blood. A discussion of the use of
25 prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

For example, when a compound of the present invention contains a
30 carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as (C₁-C₈)alkyl, (C₂-C₁₂)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-

(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(C₁-C₂)alkylamino(C₂-C₃)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C₁-C₂)alkyl, N,N-di(C₁-C₂)alkylcarbamoyl-(C₁-C₂)alkyl and piperidino-, pyrrolidino- or morpholino(C₂-C₃)alkyl.

Similarly, when a compound of the present invention comprises an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as (C₁-C₆)alkanoyloxymethyl, 1-((C₁-C₆)alkanoyloxy)ethyl, 1-methyl-1-((C₁-C₆)alkanoyloxy)ethyl, (C₁-C₆)alkoxycarbonyloxymethyl, N-(C₁-C₆)alkoxycarbonylaminomethyl, succinoyl, (C₁-C₆)alkanoyl, α-amino(C₁-C₄)alkanoyl, arylacyl and α-aminoacyl, or α-aminoacyl-α-aminoacyl, where each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)₂, -P(O)(O(C₁-C₆)alkyl)₂ or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate).

When a compound of the present invention comprises an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as R^X-carbonyl, R^XO-carbonyl, NR^XR^X-carbonyl where R^X and R^X are each independently (C₁-C₁₀)alkyl, (C₃-C₇)cycloalkyl, benzyl, or R^X-carbonyl is a natural α-aminoacyl or natural α-aminoacyl-natural α-aminoacyl, -C(OH)C(O)OY^X wherein Y^X is H, (C₁-C₆)alkyl or benzyl), -C(OY^{X0})Y^{X1} wherein Y^{X0} is (C₁-C₄)alkyl and Y^{X1} is (C₁-C₆)alkyl, carboxy(C₁-C₆)alkyl, amino(C₁-C₄)alkyl or mono-N- or di-N,N-(C₁-C₆)alkylaminoalkyl, -C(Y^{X2})Y^{X3} wherein Y^{X2} is H or methyl and Y^{X3} is mono-N- or di-N,N-(C₁-C₆)alkylamino, morpholino, piperidin-1-yl or pyrrolidin-1-yl.

The expression "pharmaceutically acceptable salt" refers to nontoxic anionic salts containing anions such as (but not limited to) chloride, bromide, iodide, sulfate, bisulfate, phosphate, acetate, maleate, fumarate, oxalate, lactate, tartrate, citrate, gluconate, methanesulfonate and 4-toluene-sulfonate. The expression also refers to nontoxic cationic salts such as (but not limited to) sodium, potassium, calcium, magnesium, ammonium or protonated benzathine (N,N'-dibenzylethylenediamine),

choline, ethanolamine, diethanolamine, ethylenediamine, meglamine (N-methyl-glucamine), benethamine (N-benzylphenethylamine), piperazine or tromethamine (2-amino-2-hydroxymethyl-1,3-propanediol).

It will be recognized that the compounds of this invention can exist in
5 radiolabelled form, i.e., said compounds may contain one or more atoms containing an atomic mass or mass number different from the atomic mass or mass number ordinarily found in nature. Radioisotopes of hydrogen, carbon, phosphorous, fluorine and chlorine include ^3H , ^{14}C , ^{32}P , ^{35}S , ^{18}F and ^{36}Cl , respectively. Compounds of this invention which contain those radioisotopes and/or other radioisotopes of other atoms
10 are within the scope of this invention. Tritiated, i.e., ^3H , and carbon-14, i.e., ^{14}C , radioisotopes are particularly preferred for their ease of preparation and detectability. Radiolabelled compounds of this invention can generally be prepared by methods well known to those skilled in the art. Conveniently, such radiolabelled compounds can be prepared by carrying out the procedures disclosed herein except substituting
15 a readily available radiolabelled reagent for a non-radiolabelled reagent.

It will be recognized by persons of ordinary skill in the art that some of the compounds of this invention have at least one asymmetric carbon atom and therefore are enantiomers or diastereomers. Diastomeric mixtures can be separated into their individual diastereomers on the basis of their physicochemical differences by
20 methods known *per se* as, for example, chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastomeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing, including both chemical hydrolysis methods and microbial lipase
25 hydrolysis methods, e.g., enzyme catalyzed hydrolysis) the individual diastereomers to the corresponding pure enantiomers. All such isomers, including diastereomers, enantiomers and mixtures thereof are considered as part of this invention. Also, some of the compounds of this invention are atropisomers (e.g., substituted biaryls) and are considered as part of this invention.

30 In addition, when the compounds of this invention, including the compounds of Formula I or the bisphosphonates, form hydrates or solvates, they are also within the scope of the invention.

Administration of the compounds of this invention can be via any method that delivers a compound of this invention systemically and/or locally. These methods

include oral, parenteral, and intraduodenal routes, etc. Generally, the compounds of this invention are administered orally, but parenteral administration (e.g., intravenous, intramuscular, transdermal, subcutaneous, rectal or intramedullary) may be utilized, for example, where oral administration is inappropriate for the target or where the
5 patient is unable to ingest the drug.

The compounds of this invention may also be applied locally to a site in or on a patient in a suitable carrier or diluent.

2MD and other 2-alkylidene-19-nor-vitamin D derivatives of the present invention can be administered to a human patient in the range of about 0.01 $\mu\text{g}/\text{day}$ to about 10 $\mu\text{g}/\text{day}$. A preferred dosage range is about 0.05 $\mu\text{g}/\text{day}$ to about 1
10 $\mu\text{g}/\text{day}$ and a more preferred dosage range is about 0.1 $\mu\text{g}/\text{day}$ to about 0.4 $\mu\text{g}/\text{day}$.

Normally the dosage of bisphosphonate is such that a single dose of the bisphosphonate active ingredient from 0.002 mg/kg to 20.0 mg/kg, especially 0.01 mg/kg to 10.0 mg/kg, is administered to the patient in need thereof. The term
15 "mg/kg" means the milligrams of bisphosphonate per kilogram of body weight of the patient. Examples of commercially available dosage forms of bisphosphonates include 5 mg, 30 mg and 35 mg oral tablets of risedronate as its sodium salt (risedronate sodium), which is marketed as Actonel[®] and of 5 mg, 10 mg, 35 mg, 40 mg and 70 mg oral tablets of alendronate, also as its sodium salt (alendronate
20 sodium), which is marketed as Fosamax[®]. The dose of bisphosphonate can be given, for example, daily, twice a week or once a week.

The amount and timing of administration will, of course, be dependent on the subject being treated, on the severity of the affliction, on the manner of administration and on the judgment of the prescribing physician. Thus, because of
25 patient to patient variability, the dosages given herein are guidelines and the physician may titrate doses of the drug to achieve the treatment that the physician considers appropriate for the patient. In considering the degree of treatment desired, the physician must balance a variety of factors such as age of the patient, presence of preexisting disease, as well as presence of other diseases. The dose
30 may be given once a day or more than once a day and may be given in a sustained release or controlled release formulation. It is also possible to administer the compounds using a combination of an immediate release and a controlled release and/or sustained release formulation.

The administration of 2MD or other 2-alkylidene-19-nor-vitamin D derivative and a bisphosphonate or the combination thereof can be according to any continuous or intermittent dosing schedule. Once a day, multiple times a day, once a week, multiple times a week, once every two weeks, multiple times every two
5 weeks, once a month, multiple times a month, once every two months, once every three months, once every six months and once a year dosing are non-limiting examples of dosing schedules for 2MD or another 2-alkylidene-19-nor-vitamin D derivative and a bisphosphonate or the combination thereof.

The compounds of the present invention are generally administered in the
10 form of a pharmaceutical composition comprising at least one of the compounds of this invention together with a pharmaceutically acceptable vehicle or diluent. Thus, the compounds of this invention can be administered in any conventional oral, parenteral, rectal or transdermal dosage form.

For oral administration a pharmaceutical composition can take the form of
15 solutions, suspensions, tablets, pills, capsules, powders, and the like. Tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate are employed along with various disintegrants such as starch and preferably potato or tapioca starch and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
20 Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are
25 desired for oral administration, the compounds of this invention can be combined with various sweetening agents, flavoring agents, coloring agents, emulsifying agents and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof. One example of an acceptable formulation for 2MD and other 2-alkylidene-19-nor-vitamin D derivatives is a soft
30 gelatin capsule containing neobe oil in which the 2MD or other 2-alkylidene-19-nor-vitamin D derivative has been dissolved. Other suitable formulations will be apparent to those skilled in the art.

For purposes of parenteral administration, solutions in sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions

of the corresponding water-soluble salts. Such aqueous solutions may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.

For purposes of transdermal (e.g., topical) administration, dilute sterile, aqueous or partially aqueous solutions (usually in about 0.1% to 5% concentration), otherwise similar to the above parenteral solutions, are prepared.

Methods of preparing various pharmaceutical compositions with a certain amount of active ingredient are known, or will be apparent in light of this disclosure, to those skilled in this art. For examples of methods of preparing pharmaceutical compositions, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 19th Edition (1995).

Another aspect of the present invention is a kit comprising:

- a. an amount of a 2-alkylidene-19-nor-vitamin D derivative, such as a compound of Formula I, and a pharmaceutically acceptable carrier or diluent in a first unit dosage form;
- b. an amount of a bisphosphonate, and a pharmaceutically acceptable carrier or diluent in a second unit dosage form; and
- c. a container.

The kit comprises two separate pharmaceutical compositions: a 2-alkylidene-19-nor-vitamin D derivative, such as a compound of Formula I and a second compound as described above. The kit comprises container means for containing the separate compositions such as a divided bottle or a divided foil packet, however, the separate compositions may also be contained within a single, undivided container. Typically, the kit comprises directions for the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.

An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs

generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process recesses are formed in the plastic foil. The recesses have the size and shape of the tablets or capsules to be packed. Next, the tablets or capsules are placed in the recesses and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are sealed in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.



It may be desirable to provide a memory aid on the kit, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen which the dosage form so specified should be ingested. Another example of such a memory aid is a calendar printed on the card e.g., as follows "First Week, Monday, Tuesday, ...etc.... Second Week, Monday, Tuesday,..." etc. Other variations of memory aids will be readily apparent. A "daily dose" can be a single tablet or capsule or several tablets or capsules to be taken on a given day. Also, a daily dose of a Formula I compound, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug can consist of one tablet or capsule while a daily dose of the second compound can consist of several tablets or capsules and vice versa. The memory aid should reflect this.


In another specific embodiment of the invention, a dispenser designed to dispense the daily doses one at a time in the order of their intended use is provided. Preferably, the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen. An example of such a memory-aid is a mechanical counter which indicates the number of daily doses that have been dispensed. Another example of such a memory-aid is a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.

The 2-alkylidene-19-nor-vitamin D derivative and the bisphosphonate can be administered in the same dosage form or in different dosage forms at the same time or at different times. All variations of administration methods are contemplated. A

preferred method of administration is to administer the combination in the same dosage form at the same time. Another preferred administration method is to administer the 2-alkylidene-19-nor-vitamin D derivative in one dosage form and the bisphosphonate in another, both of which are taken at the same time.

- 5 The preparation of 1α -hydroxy-2-alkyl-19-nor-vitamin D compounds, particularly 1α -hydroxy-2-methyl-19-nor-vitamin D compounds, having the basic structure I can be accomplished by a common general method, i.e., the condensation of a bicyclic Windaus-Grundmann type ketone II with the allylic phosphine oxide III to the corresponding 2-methylene-19-nor-vitamin D analogs IV followed by deprotection at C-1 and C-3 in the latter compounds:
- 10






5 In the structures II, III, and IV groups Y_1 and Y_2 and R represent groups defined above; Y_1 and Y_2 are preferably hydroxy-protecting groups, it being also understood that any functionalities in R that might be sensitive, or that interfere with the condensation reaction, be suitably protected as is well-known in the art. The process shown above represents an application of the convergent synthesis concept, which

10 has been applied effectively for the preparation of vitamin D compounds [e.g., Lythgoe et al., *J. Chem. Soc. Perkin Trans. 1*, 590 (1978); Lythgoe, *Chem. Soc. Rev.* 9, 449 (1983); Toh et al., *J. Org. Chem.* 48, 1414 (1983); Baggiolini et al., *J. Org. Chem.* 51, 3098 (1986); Sardina et al., *J. Org. Chem.* 51, 1264 (1986); *J. Org. Chem.* 51, 1269 (1986); DeLuca et al., U.S. Pat. No. 5,086,191; DeLuca et al., U.S. Pat. No.


15 5,536,713].

Hydrindanones of the general structure II are known, or can be prepared by known methods. Specific important examples of such known bicyclic ketones are the structures with the side chains (a), (b), (c) and (d) described above, i.e., 25-hydroxy Grundmann's ketone (f) [Baggiolini et al., *J. Org. Chem.* 51, 3098 (1986)];


20 Grundmann's ketone (g) [Inhoffen et al., *Chem. Ber.* 90, 664 (1957)]; 25-hydroxy Windaus ketone (h) [Baggiolini et al., *J. Org. Chem.* 51, 3098 (1986)] and Windaus ketone (i) [Windaus et al., *Ann.*, 524, 297 (1936)]:




(f)



(g)



(h)



(i)

For the preparation of the required phosphine oxides of general structure III, a new synthetic route has been developed starting from methyl quinate derivative 1, easily obtained from commercial (1R,3R,4S,5R)-(-)-quinic acid as described by Perlman et al., Tetrahedron Lett. 32, 7663 (1991) and DeLuca et al., U.S. Pat. No. 5,086,191. The overall process of transformation of the starting methyl ester 1 into the desired A-ring synthons, is summarized by the Scheme I. Thus, the secondary 4-hydroxyl group of 1 was oxidized with RuO₄ (a catalytic method with RuCl₃ and NaIO₄ as co-oxidant). Use of such a strong oxidant was necessary for an effective oxidation process of this very hindered hydroxyl. However, other more commonly used oxidants can also be applied (e.g., pyridinium dichromate), although the reactions usually require much longer time for completion. The second step of the synthesis comprises the Wittig reaction of the sterically hindered 4-keto compound 2 with the ylide prepared from methyltriphenylphosphonium bromide and n-butyllithium. Other bases can be also used for the generation of the reactive methylenephosphorane, like t-BuOK, NaNH₂, NaH, KHMPT, NaN(TMS)₂, etc. For the preparation of the 4-methylene compound 3 some described modifications of the Wittig process can be used, e.g., reaction of 2 with activated methylenetriphenylphosphorane [Corey et al., Tetrahedron Lett. 26, 555 (1985)]. Alternatively, other methods widely used for methylenation of unreactive ketones can be applied, e.g., Wittig-Horner reaction with the PO-ylid obtained from methyldiphenylphosphine oxide upon deprotonation with n-butyllithium [Schosse et al., Chimia 30, 197 (1976)], or reaction of ketone with sodium methylsulfinate [Corey et al., J. Org. Chem. 28, 1128 (1963)] and potassium methylsulfinate [Greene et al., Tetrahedron Lett. 3755 (1976)]. Reduction of the ester 3 with lithium aluminum hydride or other suitable reducing agent (e.g., DIBALH) provided the diol 4 which was subsequently oxidized by sodium periodate to the cyclohexanone derivative 5. The next step of the process comprises the Peterson reaction of the ketone 5 with methyl(trimethylsilyl)acetate. The resulting allylic ester 6 was treated with diisobutylaluminum hydride and the formed allylic alcohol 7 was in turn transformed to the desired A-ring phosphine oxide 8. Conversion of 7 to 8 involved 3 steps, namely, in situ tosylation with n-butyllithium and p-toluenesulfonyl chloride, followed by reaction with diphenylphosphine lithium salt and oxidation with hydrogen peroxide.

Several 2-methylene-19-nor-vitamin D compounds of the general structure IV may be synthesized using the A-ring synthon 8 and the appropriate Windaus-

Grundmann ketone II having the desired side chain structure. Thus, for example, Wittig-Horner coupling of the lithium phosphinoxy carbanion generated from 8 and n-butyllithium with the protected 25-hydroxy Grundmann's ketone 9 prepared according to published procedure [Sicinski et al., *J. Med. Chem.* 37, 3730 (1994)] gave the
5 expected protected vitamin compound 10. This, after deprotection with AG 50W-X4 cation exchange resin afforded 1 α ,25-dihydroxy-2-methylene-19-nor-vitamin D₃ (11).

The C-20 epimerization was accomplished by the analogous coupling of the phosphine oxide 8 with protected (20S)-25-hydroxy Grundmann's ketone 13 (SCHEME II) and provided 19-nor-vitamin 14 which after hydrolysis of the hydroxy-
10 protecting groups gave (20S)-1 α ,25-dihydroxy-2-methylene-19-nor-vitamin D₃ (15). As noted above, other 2-methylene-19-nor-vitamin D analogs may be synthesized by the method disclosed herein. For example, 1 α -hydroxy-2-methylene-19-nor-vitamin D₃ can be obtained by providing the Grundmann's ketone (g).

All documents cited in this application, including patents and patent
15 applications, are hereby incorporated by reference. The examples presented below are intended to illustrate particular embodiments of the invention and are not intended to limit the invention, including the claims, in any manner.

Examples

20 The following abbreviations are used in this application.

NMR	nuclear magnetic resonance
mp	melting point
H	hydrogen
h	hour(s)
25 min	minutes
t-Bu	tert-butyl
THF	tetrahydrofuran
n-BuLi	n-butyl lithium
MS	mass spectra
30 HPLC	high pressure liquid chromatography
SEM	standard error measurement
Ph	phenyl
Me	methyl
Et	ethyl

DIBALH	diisobutylaluminum hydride
LDA	lithium diisopropylamide

The preparation of compounds of Formula I were set forth in U.S. Patent No. 5,843,928 as follows:

In these examples, specific products identified by Arabic numerals (e.g., 1, 2, 3, etc.) refer to the specific structures so identified in the preceding description and in the Scheme I and Scheme II.

EXAMPLE 1

Preparation of 1 α ,25-dihydroxy-2-methylene-19-nor-vitamin D₃ (11)

Referring first to Scheme I the starting methyl quinate derivative 1 was obtained from commercial (-)-quinic acid as described previously [Perlman et al., Tetrahedron Lett. 32, 7663 (1991) and DeLuca et al., U.S. Pat. No. 5,086,191]. 1:mp. 82°-82.5°C. (from hexane), ¹H NMR(CDCl₃) δ 0.098, 0.110, 0.142, and 0.159 (each 3H, each s, 4xSiCH₃), 0.896 and 0.911 (9H and 9H, each s, 2xSi-t-Bu), 1.820 (1H, dd, J=13.1, 10.3 Hz), 2.02 (1H, ddd, J=14.3, 4.3, 2.4 Hz), 2.09 (1H, dd, J=14.3, 2.8 Hz), 2.19 (1H, ddd, J= 13.1, 4.4, 2.4 Hz), 2.31 (1H, d, J=2.8 Hz, OH), 3.42 (1H, m; after D₂O dd, J=8.6, 2.6 Hz), 3.77 (3H,s), 4.12 (1H,m), 4.37 (1H, m), 4.53 (1H,br s, OH).

(a) Oxidation of 4-hydroxy group in methyl quinate derivative 1. (3R,5R)-3,5-Bis[(tert-butyl(dimethylsilyl)oxy)]-1-hydroxy-4-oxocyclohexanecarboxylic Acid Methyl Ester (2). To a stirred mixture of ruthenium (III) chloride hydrate (434 mg, 2.1 mmol) and sodium periodate (10.8 g, 50.6 mmol) in water (42 mL) was added a solution of methyl quinate 1 (6.09 g, 14 mmol) in CCl₄/CH₃CN (1:1, 64 mL). Vigorous stirring was continued for 8 h. Few drops of 2-propanol were added, the mixture was poured into water and extracted with chloroform. The organic extracts were combined, washed with water, dried (MgSO₄) and evaporated to give a dark oily residue (ca. 5 g) which was purified by flash chromatography. Elution with hexane/ethyl acetate (8:2) gave pure, oily 4-ketone 2 (3.4 g, 56%): ¹H NMR (CDCl₃) δ 0.054, 0.091, 0.127, and 0.132 (each 3H, each s, 4xSiCH₃), 0.908 and 0.913 (9H and

9H, each s, 2xSi-t-Bu), 2.22 (1H, dd, J=13.2, 11.7 Hz), 2.28 (1H, ~dt J=14.9, 3.6 Hz), 2.37 (1H, dd, J=14.9, 3.2 Hz), 2.55 (1H, ddd, J=13.2, 6.4, 3.4 Hz), 3.79 (3H,s), 4.41 (1H, t, J~3.5 Hz), 4.64 (1H, s, OH), 5.04 (1H, dd, J=11.7, 6.4 Hz); MS m/z (relative intensity) no M+, 375 (M+-t-Bu, 32), 357 (M+-t-Bu-H₂O, 47), 243 (31), 225 (57), 73 (100).

(b) Wittig reaction of the 4-ketone 2

(3R,5R)-3,5-Bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-methylenecyclohexanecarboxylic Acid Methyl Ester (3). To the methyltriphenylphosphonium bromide (2.813 g, 7.88 mmol) in anhydrous THF (32 mL) at 0°C. was added dropwise n-BuLi (2.5M in hexanes, 6.0 mL, 15 mmol) under argon with stirring. Another portion of MePh₃P⁺Br⁻ (2.813 g, 7.88 mmol) was then added and the solution was stirred at 0°C. for 10 min. and at room temperature for 40 min. The orange-red mixture was again cooled to 0°C. and a solution of 4-ketone 2 (1.558 g, 3.6 mmol) in anhydrous THF (16+2 mL) was siphoned to reaction flask during 20 min. The reaction mixture was stirred at 0°C. for 1 h. and at room temperature for 3h. The mixture was then carefully poured into brine cont. 1% HCl and extracted with ethyl acetate and benzene. The combined organic extracts were washed with diluted NaHCO₃ and brine, dried (MgSO₄) and evaporated to give an orange oily residue (ca. 2.6 g) which was purified by flash chromatography. Elution with hexane/ethyl acetate (9:1) gave pure 4-methylene compound 3 as a colorless oil (368 mg, 24%): ¹H NMR (CDCl₃) δ 0.078, 0.083, 0.092, and 0.115 (each 3H, each s, 4xSiCH₃), 0.889 and 0.920 (9H and 9H, each s, 2xSi-t-Bu), 1.811 (1H, dd, J=12.6, 11.2 Hz), 2.10 (2H, m), 2.31 (1H, dd, J=12.6, 5.1 Hz), 3.76 (3H, s), 4.69 (1H, t, J=3.1 Hz), 4.78 (1H, m), 4.96 (2H, m; after D₂O 1H, br s), 5.17 (1H, t, J=1.9 Hz); MS m/z (relative intensity) no M+, 373 (M+-t-Bu, 57), 355 (M+-t-Bu -H₂O, 13), 341 (19), 313 (25), 241 (33), 223 (37), 209 (56), 73 (100).

(c) Reduction of ester group in the 4-methylene compound 3.

[(3R,5R)-3,5-Bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-methylenecyclohexyl]methanol (4). (i) To a stirred solution of the ester 3 (90 mg, 0.21 mmol) in anhydrous THF (8 mL) lithium aluminum hydride (60 mg, 1.6 mmol) was added at 0°C. under argon. The cooling bath was removed after 1 h. and the stirring was continued at 6°C. for 12 h. and at room temperature for 6 h. The excess

- of the reagent was decomposed with saturated aq. Na_2SO_4 , and the mixture was extracted with ethyl acetate and ether, dried (MgSO_4) and evaporated. Flash chromatography of the residue with hexane/ethyl acetate (9:1) afforded unreacted substrate (12 mg) and a pure, crystalline diol 4 (35 mg, 48% based on recovered
- 5 ester 3): ^1H NMR ($\text{CDCl}_3+\text{D}_2\text{O}$) δ 0.079, 0.091, 0.100, and 0.121 (each 3H, each s, $4\times\text{SiCH}_3$), 0.895 and 0.927 (9H and 9H, each s, $2\times\text{Si-t-Bu}$), 1.339 (1H, t, $J\sim 12$ Hz), 1.510 (1H, dd, $J=14.3, 2.7$ Hz), 2.10 (2H, m), 3.29 and 3.40 (1H and 1H, each d, $J=11.0$ Hz), 4.66 (1H, t, $J\sim 2.8$ Hz), 4.78 (1H, m), 4.92 (1H, t, $J=1.7$ Hz), 5.13 (1H, t, $J=2.0$ Hz); MS m/z (relative intensity) no M^+ , 345 ($\text{M}^+-\text{t-Bu}$, 8), 327 ($\text{M}^+-\text{t-Bu-H}_2\text{O}$,
- 10 22), 213 (28), 195 (11), 73 (100).
- (ii) Diisobutylaluminum hydride (1.5M in toluene, 2.0 mL, 3 mmol) was added to a solution of the ester 3 (215 mg, 0.5 mmol) in anhydrous ether (3 mL) at -78°C . under argon. The mixture was stirred at -78°C . for 3 h. and at -24°C . for 1.5 h., diluted with ether (10 mL) and quenched by the slow addition of 2N potassium sodium tartrate.
- 15 The solution was warmed to room temperature and stirred for 15 min., the poured into brine and extracted with ethyl acetate and ether. The organic extracts were combined, washed with diluted (ca. 1%) HCl, and brine, dried (MgSO_4) and evaporated. The crystalline residue was purified by flash chromatography. Elution with hexane/ethyl acetate (9:1) gave crystalline diol 4 (43 mg, 24%).
- 20
- (d) Cleavage of the vicinal diol 4
- (3R,5R)-3,5-Bis[(*tert*-butyldimethylsilyl)oxy]-4-methylenecyclohexanone (5). Sodium periodate saturated water (2.2 mL) was added to a solution of the diol 4 (146 mg, 0.36 mmol) in methanol (9 mL) at 0°C . The solution was stirred at 0°C . for 1 h.,
- 25 poured into brine and extracted with ether and benzene. The organic extracts were combined, washed with brine, dried (MgSO_4) and evaporated. An oily residue was dissolved in hexane (1 mL) and applied on a silica Sep-Pak cartridge. Pure 4-methylenecyclohexanone derivative 5 (110 mg, 82%) was eluted with hexane/ethyl acetate (95:5) as a colorless oil: ^1H NMR (CDCl_3) δ 0.050 and 0.069 (6H and 6H,
- 30 each s, $4\times\text{SiCH}_3$), 0.881 (18H, s, $2\times\text{Si-t-Bu}$), 2.45 (2H, ddd, $J=14.2, 6.9, 1.4$ Hz), 2.64 (2H, ddd, $J=14.2, 4.6, 1.4$ Hz), 4.69 (2H, dd, $J=6.9, 4.6$ Hz), 5.16 (2H, s); MS M/z (relative intensity) no M^+ , 355 (M^+-Me , 3), 313 ($\text{M}^+-\text{t-Bu}$, 100), 73 (76).

(e) Preparation of the allylic ester 6

[(3'R,5'R)-3',5'-Bis[(tert-butyldimethylsilyl)oxy]-4'-methylenecyclohexylidene]acetic
Acid Methyl Ester (6). To a solution of diisopropylamine (37 μ L, 0.28 mmol) in
anhydrous THF (200 μ L) was added n-BuLi (2.5M in hexanes, 113 μ L, 0.28 mmol)
under argon at -78°C . with stirring, and methyl(trimethylsilyl)acetate (46 μ L, 0.28
5 mmol) was then added. After 15 min., the keto compound 5 (49 mg, 0.132 mmol) in
anhydrous THF (200+80 μ L) was added dropwise. The solution was stirred at -78°C .
for 2 h. and the reaction mixture was quenched with saturated NH_4Cl , poured into
brine and extracted with ether and benzene. The combined organic extracts were
washed with brine, dried (MgSO_4) and evaporated. The residue was dissolved in
10 hexane (1 mL) and applied on a silica Sep-Pak cartridge. Elution with hexane and
hexane/ethyl acetate (98:2) gave a pure allylic ester 6 (50 mg, 89%) as a colorless
oil: ^1H NMR (CDCl_3) δ 0.039, 0.064, and 0.076 (6H, 3H, and 3H, each s, $4\times\text{SiCH}_3$),
0.864 and 0.884 (9H and 9H, each s, $2\times\text{Si-t-Bu}$), 2.26 (1H, dd, $J=12.8, 7.4$ Hz), 2.47
(1H, dd, $J=12.8, 4.2$ Hz), 2.98 (1H, dd, $J=13.3, 4.0$ Hz), 3.06 (1H, dd, $J=13.3, 6.6$ Hz),
15 3.69 (3H, s), 4.48 (2H, m), 4.99 (2H, s), 5.74 (1H, s); MS m/z (relative intensity) 426
(M^+ , 2), 411 (M^+-Me , 4), 369 ($\text{M}^+-\text{t-Bu}$, 100), 263 (69).

(f) Reduction of the allylic ester 6

2-[(3'R,5'R)-3',5'-Bis[(tert-butyldimethylsilyl)oxy]-4'-methylenecyclohexylidene]ethanol
20 (7). Diisobutylaluminum hydride (1.5M in toluene, 1.6 mL, 2.4 mmol) was slowly
added to a stirred solution of the allylic ester 6 (143 mg, 0.33 mmol) in
toluene/methylene chloride (2:1, 5.7 mL) at -78°C . under argon. Stirring was
continued as -78°C . for 1 h. and at -46°C . (cyclohexanone/dry ice bath) for 25 min.
The mixture was quenched by the slow addition of potassium sodium tartrate (2N, 3
25 mL), aq. HCl (2N, 3 mL) and H_2O (12 mL), and then diluted with methylene chloride
(12 mL) and extracted with ether and benzene. The organic extracts were combined,
washed with diluted (ca. 1%) HCl, and brine, dried (MgSO_4) and evaporated. The
residue was purified by flash chromatography. Elution with hexane/ethyl acetate
(9:1) gave crystalline allylic alcohol 7 (130 mg, 97%): ^1H NMR (CDCl_3) δ 0.038, 0.050,
30 and 0.075 (3H, 3H, and 6H, each s, $4\times\text{SiCH}_3$), 0.876 and 0.904 (9H and 9H, each s,
 $2\times\text{Si-t-Bu}$), 2.12 (1H, dd $J=12.3, 8.8$ Hz), 2.23 (1H, dd, $J=13.3, 2.7$ Hz), 2.45 (1H, dd,
 $J=12.3, 4.8$ Hz), 2.51 (1H, dd, $J=13.3, 5.4$ Hz), 4.04 (1H, m; after D_2O dd, $J=12.0, 7.0$
Hz), 4.17 (1H, m; after D_2O dd, $J=12.0, 7.4$ Hz), 4.38 (1H, m), 4.49 (1H, m), 4.95 (1H,
br s), 5.05 (1H, t, $J=1.7$ Hz), 5.69 (1H, ~t, $J=7.2$ Hz); MS m/z (relative intensity) 398

(M+, 2), 383 (M+-Me, 2), 365 (M+-Me-H₂O, 4), 341 (M+-t-Bu, 78), 323 (M+-t-Bu-H₂O, 10), 73 (100).

(g) Conversion of the allylic alcohol 7 into phosphine oxide 8

5 [2-[(3'R,5'R)-3',5'-Bis[(tert-butyldimethylsilyl)oxy]-4'-methylenecyclohexylidene]ethyl]diphenylphosphine Oxide (8). To the allylic alcohol 7 (105 mg, 0.263 mmol) in anhydrous THF (2.4 mL) was added n-BuLi (2.5M in hexanes, 105 μ L, 0.263 mmol) under argon at 0°C. Freshly recrystallized tosyl chloride (50.4 mg, 0.264 mmol) was dissolved in anhydrous THF (480 μ L) and added to the allylic alcohol-BuLi solution. The mixture was stirred at 0°C. for 5 min. and set
10 aside at 0°C. In another dry flask with air replaced by argon, n-BuLi (2.5M in hexanes, 210 μ L, 0.525 mmol) was added to Ph₂PH (93 μ L, 0.534 mmol in anhydrous THF (750 μ L) at 0°C. with stirring. The red solution was siphoned under argon pressure to the solution of tosylate until the orange color persisted (ca. 1/2 of the solution was added). The resulting mixture was stirred an additional 30 min. at 0°C.,
15 and quenched by addition of H₂O (30 μ L). Solvents were evaporated under reduced pressure and the residue was redissolved in methylene chloride (2.4 mL) and stirred with 10% H₂O₂ at 0°C. for 1 h. The organic layer was separated, washed with cold aq. Sodium sulfite and H₂O, dried (MgSO₄) and evaporated. The residue was subject
20 to flash chromatography. Elution with benzene/ethyl acetate (6:4) gave semicrystalline phosphine oxide 8 (134 mg, 87%): ¹H NMR (CDCl₃) δ 0.002, 0.011 and 0.019 (3H, 3H, and 6H, each s, 4xSiCH₃), 0.855 and 0.860 (9H and 9H, each s, 2xSi-t-Bu), 2.0-2.1 (3H, br m), 2.34 (1H, m), 3.08 (1H, m), 3.19 (1H, m), 4.34 (2H, m), 4.90 and 4.94 (1H and 1H, each s.), 5.35 (1H, ~q, J=7.4 Hz), 7.46 (4H, m), 7.52 (2H,
25 m), 7.72 (4H, m); MS m/z (relative intensity) no M+, 581 (M+-1, 1), 567 (M+-Me, 3) 525 (M+-t-Bu, 100), 450 (10), 393 (48).

(h) Wittig-Horner coupling of protected 25-hydroxy Grundmann's ketone 9 with the phosphine oxide 8

30 1 α ,25-Dihydroxy-2-methylene-19-nor-vitamin D₃ (11). To a solution of phosphine oxide 8 (33.1 mg, 56.8 μ mol) in anhydrous THF (450 μ L) at 0°C. was slowly added n-BuLi (2.5M in hexanes, 23 μ L, 57.5 μ mol) under argon with stirring. The solution turned deep orange. The mixture was cooled to -78°C. and a precooled (-78°C.)

solution of protected hydroxy ketone 9 (9.0 mg, 22.8 μ mol), prepared according to published procedure [Sicinski et al., *J. Med. Chem.* 37, 3730 (1994)], in anhydrous THF (200+100 μ L) was slowly added. The mixture was stirred under argon at -78°C . for 1 h. and at 0°C . for 18 h. Ethyl acetate was added, and the organic phase was washed with brine, dried (MgSO_4) and evaporated. The residue was dissolved in hexane and applied on a silica Sep-Pak cartridge, and washed with hexane/ethyl acetate (99:1, 20 mL) to give 19-nor-vitamin derivative 10 (13.5 mg, 78%). The Sep-Pak was then washed with hexane/ethyl acetate (96:4), 10 mL) to recover some unchanged C,D-ring ketone 9 (2 mg), and with ethyl acetate (10 mL) to recover diphenylphosphine oxide (20 mg). For analytical purpose a sample of protected vitamin 10 was further purified by HPLC (6.2 mm x 25 cm Zorbax-Sil column, 4 mL/min) using hexane/ethyl acetate (99.9:0.1) solvent system. Pure compound 10 was eluted at R_v 26 mL as a colorless oil: UV (in hexane) λ_{max} 224, 253, 263 nm; ^1H NMR (CDCl_3) δ 0.025, 0.049, 0.066, and 0.080 (each 3H, each s, 4xSiCH₃), 0.546 (3H, s, 18-H₃), 0.565 (6H, q, J=7.9 Hz, 3xSiCH₂), 0.864 and 0.896 (9H and 9H, each s, 2xSi-t-Bu), 0.931 (3H, d, J=6.0 Hz, 21-H₃), 0.947 (9H, t, J=7.9 Hz, 3xSiCH₂CH₃), 1.188 (6H, s, 26- and 27-H₃), 2.00 (2H, m), 2.18 (1H, dd, J=12.5, 8.5 Hz, 4 β -H), 2.33 (1H, dd, J=13.1, 2.9 Hz, 10 β -H), 2.46 (1H, dd J=12.5, 4.5 Hz, 4 α -H), 2.52 (1H, dd, J=13.1, 5.8 Hz, 10 α -H), 2.82 (1H, br d, J=12 Hz, 9 β -H), 4.43 (2H, m, 1 β - and 3 α -H); 4.92 and 4.97 (1H and 1H, each s, =CH₂), 5.84 and 6.22 (1H and 1H, each d, J=11.0 Hz, 7- and 6-H); MS m/z (relative intensity) 758 (M^+ , 17), 729 (M^+ -Et, 6), 701 (M^+ -t-Bu, 4), 626 (100), 494 (23), 366 (50), 73 (92).

Protected vitamin 10 (4.3 mg) was dissolved in benzene (150 μ L) and the resin (AG 50W-X4, 60 mg; prewashed with methanol) in methanol (800 μ L) was added. The mixture was stirred at room temperature under argon for 17 h., diluted with ethyl acetate/ether (1:1, 4 mL) and decanted. The resin was washed with ether (8 mL) and the combined organic phases washed with brine and saturated NaHCO_3 , dried (MgSO_4) and evaporated. The residue was purified by HPLC (62 mm x 25 cm Zorbax-Sil column, 4 mL/min.) using hexane/2-propanol (9:1) solvent system. Analytically pure 2-methylene-19-nor-vitamin 11 (2.3 mg, 97%) was collected at R_v 29 mL (1 α ,25-dihydroxyvitamin D₃ was eluted at R_v 52 mL in the same system) as a white solid: UV (in EtOH) λ_{max} 243.5, 252, 262.5 nm; ^1H NMR (CDCl_3) δ 0.552 (3H, s,

18-H₃), 0.941 (3H, d, J=6.4 Hz, 21-H₃), 1.222 (6H, s, 26- and 27-H₃), 2.01 (2H, m),
2.27-2.36 (2H, m), 2.58 (1H, m), 2.80-2.88 (2H, m), 4.49 (2H, m, 1β- and 3α-H), 5.10
and 5.11 (1H and 1H, each s, =CH₂), 5.89 and 6.37 (1H and 1H, each d, J=11.3 Hz,
7- and 6-H); MS m/z (relative intensity) 416 (M⁺, 83), 398 (25), 384 (31), 380 (14),
5 351 (20), 313 (100).

EXAMPLE 2

Preparation of (20S)-1α,25-dihydroxy-2-methylene-19-nor-vitamin D₃ (15)

10

Scheme II illustrates the preparation of protected (20S)-25-hydroxy Grundmann's ketone 13, and its coupling with phosphine oxide 8 (obtained as described in Example 1).

15

(a) Silylation of hydroxy ketone 12

(20S)-25-[(Triethylsilyl)oxy]-des-A,B-cholestan-8-one (13). A solution of the ketone 12 (Tetronics, Inc. Madison, WI.; 56 mg, 0.2 mmol) and imidazole (65 mg, 0.95 mmol) in anhydrous DMF (1.2 mL) was treated with triethylsilyl chloride (95 μL, 0.56 mmol), and the mixture was stirred at room temperature under argon for 4 h. Ethyl acetate was added and water, and the organic layer was separated. The ethyl acetate layer was washed with water and brine, dried (MgSO₄) and evaporated. The residue was passed through a silica Sep-Pak cartridge in hexane/ethyl acetate (9:1) and after evaporation, purified by HPLC (9.4 mm x 25 cm Zorbax-Sil column, 4 mL/min) using hexane/ethyl acetate (9:1) solvent system. Pure protected hydroxy ketone 13 (55mg, 70%) was eluted at R_v 35 mL as a colorless oil: ¹H NMR (CDCl₃) δ 0.566 (6H, q, J=7.9 Hz, 3xSiCH₂), 0.638 (3H, s, 18-H₃), 0.859 (3H, d, J=6.0 Hz, 21-H₃), 0.947 (9H, t, J=7.9 Hz, 3xSiCH₂CH₃), 1.196 (6H, s, 26- and 27-H₃), 2.45 (1H, dd, J=11.4, 7.5 Hz, 14α-H).

20

25

30

(b) Wittig-Horner coupling of protected (20S)-25-hydroxy Grundmann's ketone 13 with the phosphine oxide 8

(20S)-1α,25-Dihydroxy-2-methylene-19-nor-vitamin D₃ (15). To a solution of phosphine oxide 8 (15.8 mg, 27.1 μmol) in anhydrous THF (200 μL) at 0°C. was

slowly added n-BuLi (2.5M in hexanes, 11 μ L, 27.5 μ mol) under argon with stirring. The solution turned deep orange. The mixture was cooled to -78°C . and a precooled (-78°C .) solution of protected hydroxy ketone 13 (8.0 mg, 20.3 μ mol) in anhydrous THF (100 μ L) was slowly added. The mixture was stirred under argon at -78°C . for 1 h. and at 0°C . for 18 h. Ethyl acetate was added, and the organic phase was washed with brine, dried (MgSO_4) and evaporated. The residue was dissolved in hexane and applied on a silica Sep-Pak cartridge, and washed with hexane/ethyl acetate (99.5:0.5, 20 mL) to give 19-nor-vitamin derivative 14 (7 mg, 45%) as a colorless oil. The Sep-Pak was then washed with hexane/ethyl acetate (96:4, 10 mL) to recover some unchanged C,D-ring ketone 13 (4 mg), and with ethyl acetate (10 mL) to recover diphenylphosphine oxide (9 mg). For analytical purpose a sample of protected vitamin 14 was further purified by HPLC (6.2 mm x 25 cm Zorbax-Sil column, 4 mL/min) using hexane/ethyl acetate (99.9:0.1) solvent system.

14: UV (in hexane) λ_{max} 244, 253.5, 263 nm; ^1H NMR (CDCl_3) δ 0.026, 0.049, 0.066 and 0.080 (each 3H, each s, 4xSiCH₃), 0.541 (3H, s, 18-H₃), 0.564 (6H, q, J=7.9 Hz, 3xSiCH₂), 0.848 (3H, d, J=6.5 Hz, 21-H₃), 0.864 and 0.896 (9H and 9H, each s, 2xSi-t-Bu), 0.945 (9H, t, J=7.9 Hz, 3xSiCH₂CH₃), 1.188 (6H, s, 26- and 27-H₃), 2.15-2.35 (4H, br m), 2.43-2.53 (3H, br m), 2.82 (1H, br d, J=12.9 Hz, 9 β -H), 4.42 (2H, m, 1 β - and 3 α -H), 4.92 and 4.97 (1H and 1H, each s, =CH₂), 5.84 and 6.22 (1H and 1H, each d, J=11.1 Hz, 7- and 6-H); MS m/z (relative intensity) 758 (M⁺, 33), 729 (M⁺-Et, 7), 701 (M⁺-t-Bu, 5), 626 (100), 494 (25), 366 (52), 75 (82), 73 (69).

Protected vitamin 14 (5.0 mg) was dissolved in benzene (160 μ L) and the resin (AG 50W-X4, 70 mg; prewashed with methanol) in methanol (900 μ L) was added. The mixture was stirred at room temperature under argon for 19 h. diluted with ethyl acetate/ether (1:1, 4 mL) and decanted. The resin was washed with ether (8 mL) and the combined organic phases washed with brine and saturated NaHCO_3 , dried (MgSO_4) and evaporated. The residue was purified by HPLC (6.2 mm x 25 cm Zorbax-Sil column, 4 mL/min.) using hexane/2-propanol (9:1) solvent system. Analytically pure 2-methylene-19-nor-vitamin 15 (2.6 mg, 95%) was collected at R_v 28 mL [(20R)-analog was eluted at R_v 29 mL and 1 α ,25-dihydroxyvitamin D₃ at R_v 52 mL in the same system] as a white solid: UV (in EtOH) λ_{max} 243.5, 252.5, 262.5nm; ^3H

NMR (CDCl₃) δ 0.551 (3H, s, 18-H₃), 0.858 (3H, d, J=6.6 Hz, 21-H₃), 1.215 (6H, s, 26- and 27-H₃), 1.95-2.04 (2H, m), 2.27-2.35 (2H, m), 2.58 (1H, dd, J=13.3, 3.0 Hz), 2.80-2.87 (2H, m), (2H, m, 1 β - and 3 α -H), 5.09 and 5.11 (1H and 1H, each s, =CH₂), 5.89 and 6.36 (1H and 1H, each d, J=11.3 Hz, 7- and 6-H); MS m/z (relative intensity) 416 (M⁺, 100), 398 (26), 380 (13), 366 (21), 313 (31).

BIOLOGICAL ACTIVITY OF 2-METHYLENE-SUBSTITUTED 19-NOR-1,25-(OH)₂D₃ COMPOUNDS AND THEIR 20S-ISOMERS

The biological activity of compounds of Formula I was set forth in U.S. Patent No. 5,843,928 as follows. The introduction of a methylene group to the 2-position of 19-nor-1,25-(OH)₂D₃ or its 20S-isomer had little or no effect on binding to the porcine intestinal vitamin D receptor. All compounds bound equally well to the porcine receptor including the standard 1,25-(OH)₂D₃. It might be expected from these results that all of the compounds would have equivalent biological activity. Surprisingly, however, the 2-methylene substitutions produced highly selective analogs with their primary action on bone. When given for 7 days in a chronic mode, the most potent compound tested was the 2-methylene-19-nor-20S-1,25-(OH)₂D₃ (Table 1). When given at 130 pmol/day, its activity on bone calcium mobilization (serum calcium) was of the order of at least 10 and possible 100-1,000 times more than that of the native hormone. Under identical conditions, twice the dose of 1,25-(OH)₂D₃ gave a serum calcium value of 13.8 mg/100 ml of serum calcium at the 130 pmol dose. When given at 260 pmol/day, it produced the astounding value of 14 mg/100 ml of serum calcium at the expense of bone. To show its selectivity, this compound produced no significant change in intestinal calcium transport at either the 130 or 260 pmol dose, while 1,25-(OH)₂D₃ produced the expected elevation of intestinal calcium transport at the only dose tested, i.e. 260 pmol/day. The 2-methylene-19-nor-1,25-(OH)₂D₃ also had extremely strong bone calcium mobilization at both dose levels but also showed no intestinal calcium transport activity. The bone calcium mobilization activity of this compound is likely to be 10-100 times that of 1,25-(OH)₂D₃. These results illustrate that the 2-methylene and the 20S-2-methylene derivatives of 19-nor-1,25-(OH)₂D₃ are selective for the mobilization of calcium from bone. Table 2 illustrates the response of both intestine and serum calcium to a single

large dose of the various compounds; again, supporting the conclusions derived from Table 1.

The results illustrate that 2-methylene-19-nor-20S-1,25-(OH)₂D₃ is extremely potent in inducing differentiation of HL-60 cells to the monocyte. The 2-methylene-19-nor compound had activity similar to 1,25-(OH)₂D₃. These results illustrate the potential of the 2-methylene-19-nor-20S-1,25-(OH)₂D₃ and 2-methylene-19-nor-1,25-(OH)₂D₃ compounds as anti-cancer agents, especially against leukemia, colon cancer, breast cancer and prostate cancer, or as agents in the treatment of psoriasis.

Competitive binding of the analogs to the porcine intestinal receptor was carried out by the method described by Dame et al. (*Biochemistry* 25, 4523-4534, 1986).

The differentiation of HL-60 promyelocytic into monocytes was determined as described by Ostrem et al (*J. Biol. Chem.* 262, 14164-14171, 1987).

TABLE 1

Response of Intestinal Calcium Transport and Serum Calcium (Bone Calcium Mobilization) Activity to Chronic Doses of 2-Methylene Derivatives of 19-Nor-1,25-(OH)₂D₃ and its 20S Isomers

Group	Dose (pmol/day/7 days)	Intestinal Calcium Transport (S/M)	Serum Calcium (mg/100 ml)
Vitamin D Deficient	Vehicle	5.5 ± 0.2	5.1 ± 0.16
1,25-(OH) ₂ D ₃ Treated	260	6.2 ± 0.4	7.2 ± 0.5
2-Methylene-19-Nor-1,25-(OH) ₂ D ₃	130	5.3 ± 0.4	9.9 ± 0.2
	260	4.9 ± 0.6	9.6 ± 0.3
2-Methylene-19-Nor-20S-1,25-(OH) ₂ D ₃	130	5.7 ± 0.8	13.8 ± 0.5
	260	4.6 ± 0.7	14.4 ± 0.6

Male weanling rats were obtained from Sprague Dawley Co. (Indianapolis, Ind.) and fed a 0.47% calcium, 0.3% phosphorus vitamin D-deficient diet for 1 week and then given the same diet containing 0.02% calcium, 0.3% phosphorus for 2 weeks. During the last week they were given the indicated dose of compound by intraperitoneal injection in 0.1 ml 95% propylene glycol and 5% ethanol each day for 7 days. The control animals received only the 0.1 ml of 95% propylene glycol, 5% ethanol.

Twenty-four hours after the last dose, the rats were sacrificed and intestinal calcium transport was determined by everted sac technique as previously described and serum calcium determined by atomic absorption spectrometry on a model 3110 Perkin Elmer instrument (Norwalk, Conn.). There were 5 rats per group and the values represent mean (\pm)SEM.

TABLE 2


Response of Intestinal Calcium Transport and Serum Calcium (Bone Calcium Mobilization) Activity to Chronic Doses of 2-Methylene Derivatives of 19-Nor-1,25-(OH) ₂ D ₃ and its 20S Isomers		
Group	Intestinal Calcium Transport (S/M)	Serum Calcium (mg/100 ml)
-D Control	4.2 \pm 0.3	4.7 \pm 0.1
1,25-(OH) ₂ D ₃	5.8 \pm 0.3	5.7 \pm 0.2
2-Methylene-19-Nor-1,25-(OH) ₂ D ₃	5.3 \pm 0.5	6.4 \pm 0.1
2-Methylene-19-Nor-20S-1,25-(OH) ₂ D ₃	5.5 \pm 0.6	8.0 \pm 0.1

10

Male Holtzman strain weanling rats were obtained from the Sprague Dawley Co. (Indianapolis, Ind.) and fed the 0.47% calcium, 0.3% phosphorus diet described by Suda et al. (J. Nutr. 100, 1049-1052, 1970) for 1 week and then fed the same diet containing 0.02% calcium and 0.3% phosphorus for 2 additional weeks. At this point, they received a single intrajugular injection of the indicated dose dissolved in 0.1 ml of 95% propylene glycol/5% ethanol. Twenty-four hours later they were sacrificed and intestinal calcium transport and serum calcium were determined as described in Table 1. The dose of the compounds was 650 pmol and there were 5 animals per group. The data are expressed as mean (\pm)SEM.

20

Accordingly, compounds of the following formulae Ia, are along with those of formula I, also encompassed by the present invention:







5


In the above formula 1a, the definitions of Y_1 , Y_2 , R_6 , R_8 and Z are as previously set forth herein. With respect to X_1 , X_2 , X_3 , X_4 , X_5 , X_6 , X_7 , X_8 and X_9 , these substituents may be the same or different and are selected from hydrogen or lower alkyl, i.e., a C₁₋₅ alkyl such as a methyl, ethyl or n-propyl. In addition, paired substituents X_1 and X_4 , or X_5 , X_2 or X_3 and X_6 or X_7 , X_4 or X_5 and X_8 or X_9 , when taken together with the three adjacent carbon atoms of the central part of the compound, which correspond to positions 8, 14, 13 or 14, 13, 17 or 13, 17, 20 respectively, can be the same or different and form a saturated or unsaturated, substituted or unsubstituted, carbocyclic 3, 4, 5, 6 or 7 membered ring.

Preferred compounds of the present invention may be represented by one of the following formulae:


20








If



Ig




- 5 In the above formulae 1b, 1c, 1d, 1e, 1f, 1g and 1h, the definitions of Y_1 , Y_2 , R_6 , R_8 , R , Z , X_1 , X_2 , X_3 , X_4 , X_5 , X_6 , X_7 , and X_8 are as previously set forth herein. The substituent Q represents a saturated or unsaturated, substituted or unsubstituted, hydrocarbon chain comprised of 0, 1, 2, 3 or 4 carbon atoms, but is preferably the group $-(CH_2)_k-$ where k is an integer equal to 2 or 3.

10


Methods for making compounds of formulae 1a-1h are known. Specifically, reference is made to International Application Number PCT/EP94/02294 filed July 7, 1994, and published January 19, 1995, under International Publication Number WO95/01960.

15


Scheme 1



Scheme 1 (continued)



Scheme II



Claims

What is claimed is:

- 5
1. A pharmaceutical composition comprising the compound 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ and a bisphosphonate.
 2. A composition of claim 1 wherein the bisphosphonate is selected from
10 tiludronate, alendronate, zoledronate, ibandronate, risedronate, etidronate, clodronate or pamidronate.
 3. A composition of claim 2 wherein the bisphosphonate is alendronate.
 - 15 4. A composition of claim 2 wherein the bisphosphonate is risedronate.
 5. A method of treating senile osteoporosis, postmenopausal osteoporosis, bone fracture, bone graft, breast cancer, prostate cancer, obesity, osteopenia, male osteoporosis, frailty, muscle damage or sarcopenia,
20 the method comprising administering to a patient in need thereof a therapeutically effective amount of 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ and a therapeutically effective amount of a bisphosphonate.
 - 25 6. The method of claim 5 wherein the 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ and bisphosphonate are administered orally.
 7. The method of claim 5 wherein the 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered parenterally.
30
 8. The method of claim 5 wherein the 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered transdermally.

9. The method of claim 5 wherein the 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ and bisphosphonate are administered substantially simultaneously.
- 5 10. The method of claim 5 wherein postmenopausal osteoporosis is treated.
- 10 11. A method of treating senile osteoporosis, postmenopausal osteoporosis, bone fracture, bone graft, breast cancer, prostate cancer, obesity, osteopenia, male osteoporosis, frailty, muscle damage or sarcopenia, the method comprising administering to a patient in need thereof a therapeutically effective amount of 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ and a therapeutically effective amount of a bisphosphonate selected from tiludronate, alendronate, zoledronate, 15 ibandronate, risedronate, etidronate, clodronate or pamidronate.
12. The method of claim 11 wherein the bisphosphonate is alendronate.
- 20 13. The method of claim 12 wherein postmenopausal osteoporosis is treated.
14. The method of claim 11 wherein the bisphosphonate is risedronate.
- 25 15. The method of claim 14 wherein postmenopausal osteoporosis is treated.

INTERNATIONAL SEARCH REPORT

PCT/IB2004/002935

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/59 A61P19/10 A61P3/02 A61P19/00 A61P35/00
 A61P3/04 A61P21/00 A61K31/663 A61K31/675

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, EMBASE, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01/28564 A (LEE KYUNG HEE ; LEE YONG OH (KR); KANG SUNG AN (KR); KIM CHANG JONG (K) 26 April 2001 (2001-04-26) preparative examples 1-15 page 16, lines 5-27 page 9, line 19 - page 11, line 23 page 5, line 16 - page 6, line 1 page 1, line 6 - page 3, line 9 -----	1-15
Y	US 6 416 737 B1 (MANOLAGAS STAVROS C ET AL) 9 July 2002 (2002-07-09) column 18, line 10 - column 19, line 67 ----- -/--	1,5-10

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 November 2004

Date of mailing of the international search report

01/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Bazzanini, R

INTERNATIONAL SEARCH REPORT

PCT/IB2004/002935

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01/15703 A (SANTORA ARTHUR C II ; MERCK & CO INC (US); YATES A JOHN (US); DAIFOTIS) 8 March 2001 (2001-03-08) claims 1,4,5,16 page 30, lines 10-30 page 15, line 21 - page 16, line 25 page 12, line 26 - page 13, line 18 page 7, lines 6-15 page 1, lines 22-31 -----	1-15
Y	WO 01/13922 A (LITTLE DAVID G ; ROYAL ALEXANDRA HOSPITAL FOR C (AU)) 1 March 2001 (2001-03-01) claims 1,4-6,8,11-13,15,17-20 page 6, lines 2-9 page 1, lines 3-7 -----	1-15
Y	WO 00/59485 A (NOVARTIS ERFIND VERWALT GMBH ; NOVARTIS AG (CH); BATAILLE FRANCOIS REG) 12 October 2000 (2000-10-12) claims 1,7 page 8, paragraph 2-5 page 6, paragraph 2 page 4, paragraph 6 -----	1-15
Y	WO 02/087555 A (NOVARTIS ERFIND VERWALT GMBH ; NOVARTIS AG (CH); SEAMAN JOHN J (US)) 7 November 2002 (2002-11-07) claims 1,9-12 -----	1-15
Y	WO 02/080933 A (LITTLE DAVID GRAHAM ; ROYAL ALEXANDRA HOSPITAL FOR C (AU)) 17 October 2002 (2002-10-17) claims 1,10-12,25 page 14, line 35 - page 15, line 15 page 7, line 33 - page 8, line 8 page 1, lines 3-6 -----	1-15
Y	US 5 843 928 A (RAFAL SICINSKI R ET AL) 1 December 1998 (1998-12-01) column 1, lines 10-28 column 4, lines 6-52 column 6, line 54 - column 7, line 41 column 15, line 34 - column 17, line 32 claims 17-29 -----	1-15
	-/--	

INTERNATIONAL SEARCH REPORT

PCT/IB2004/002935

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>SHEVDE NIRUPAMA K ET AL: "A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 99, no. 21, 15 October 2002 (2002-10-15), pages 13487-13491, XP002247340 ISSN: 0027-8424 abstract page 13487, left-hand column, paragraphs 1,2 page 13490, right-hand column, paragraph 1 - page 13491, right-hand column, paragraph 2</p> <p>-----</p>	1-15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2004/002935

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 5-15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/IB2004/002935

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0128564	A	26-04-2001	KR 2001037885 A	15-05-2001
			AU 1059601 A	30-04-2001
			CN 1420777 T	28-05-2003
			EP 1229917 A1	14-08-2002
			JP 2003514776 T	22-04-2003
			WO 0128564 A1	26-04-2001
US 6416737	B1	09-07-2002	AU 1525700 A	05-06-2000
			WO 0028982 A2	25-05-2000
WO 0115703	A	08-03-2001	US 6432932 B1	13-08-2002
			AU 741818 B2	13-12-2001
			AU 6406900 A	26-03-2001
			NZ 508507 A	30-01-2004
			WO 0115703 A1	08-03-2001
			US 2002065252 A1	30-05-2002
			US 2001018431 A1	30-08-2001
WO 0113922	A	01-03-2001	WO 0113922 A1	01-03-2001
			AU 6548800 A	19-03-2001
			BR 0013416 A	30-04-2002
			CA 2381302 A1	01-03-2001
			CN 1370071 T	18-09-2002
			EP 1214079 A1	19-06-2002
			HU 0202396 A2	28-11-2002
			JP 2003507426 T	25-02-2003
			NO 20020784 A	18-02-2002
			NZ 517538 A	25-07-2003
			PL 353485 A1	17-11-2003
			SK 2382002 A3	10-09-2002
			ZA 200202160 A	17-06-2003
WO 0059485	A	12-10-2000	AU 4543500 A	23-10-2000
			WO 0059485 A2	12-10-2000
			EP 1165139 A2	02-01-2002
			JP 2002541096 T	03-12-2002
			US 2003212048 A1	13-11-2003
			US 2002061866 A1	23-05-2002
WO 02087555	A	07-11-2002	BR 0209365 A	08-06-2004
			CA 2443625 A1	07-11-2002
			CZ 20032950 A3	16-06-2004
			WO 02087555 A2	07-11-2002
			EP 1418897 A2	19-05-2004
			HU 0400096 A2	28-04-2004
			JP 2004528340 T	16-09-2004
			NO 20034877 A	19-12-2003
			SK 13512003 A3	03-08-2004
			US 2004157799 A1	12-08-2004
WO 02080933	A	17-10-2002	WO 02062351 A1	15-08-2002
			WO 02080933 A1	17-10-2002
			BR 0116862 A	13-01-2004
			CA 2435552 A1	15-08-2002
			CZ 20032408 A3	16-06-2004
			EP 1365769 A1	03-12-2003
			EP 1383509 A1	28-01-2004
			HU 0303013 A2	29-12-2003

INTERNATIONAL SEARCH REPORT

PCT/IB2004/002935

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 02080933 A		JP 2004527479 T	09-09-2004
		JP 2004526747 T	02-09-2004
		NO 20033446 A	01-10-2003
		SK 9862003 A3	03-02-2004
		US 2004097469 A1	20-05-2004
		US 2004157798 A1	12-08-2004
<hr/>			
US 5843928 A	01-12-1998	AT 223890 T	15-09-2002
		AU 714253 B2	23-12-1999
		AU 6280198 A	12-10-1998
		CA 2283829 A1	24-09-1998
		DE 69807852 D1	17-10-2002
		DK 970047 T3	11-11-2002
		EP 0970047 A1	12-01-2000
		ES 2179451 T3	16-01-2003
		JP 2001504135 T	27-03-2001
		NO 994398 A	10-09-1999
		NZ 337503 A	29-09-2000
		PT 970047 T	31-01-2003
		US 2002087015 A1	04-07-2002
		WO 9841501 A1	24-09-1998
		US 5936133 A	10-08-1999
		US 2003181427 A1	25-09-2003
		US 6392071 B1	21-05-2002
		US 2004167104 A1	26-08-2004
<hr/>			